Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas

Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas

Resumen: Los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2) han demostrado su beneficio cardiovascular y renal en pacientes con diabetes mellitus tipo 2, insuficiencia cardiaca (IC) o enfermedad renal crónica (ERC). Desde los primeros estudios, con estos fármacos se objetivó un increm...

Full description

Bibliographic Details
Main Authors:	Aleix Cases, Secundino Cigarrán, José Luis Górriz, Julio Nuñez
Format:	Article
Language:	Spanish
Published:	Elsevier 2024-03-01
Series:	Nefrología
Subjects:	SGLT2 inhibitors Anemia Diabetes Heart failure Chronic kidney disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S0211699523001728

Similar Items

Efectividad y seguridad comparada de inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2) en diabetes mellitus tipo 2: revisión rápida de revisiones sistemáticas y metaanálisis
by: K. Chacón, et al.
Published: (2021-06-01)

Los inhibidores del cotransportador sodio-glucosa tipo 2 podrían resultar igual de beneficiosos que la metformina para el tratamiento de primera línea de la diabetes tipo 2
by: Maria Victoria Salgado
Published: (2022-10-01)

Inibitori del cotrasportatore sodio-glucosio di tipo 2 in pazienti sottoposti a trapianto renale
by: Aris Tsalouchos
Published: (2023-11-01)

Inhibidores del SGTL-2 en pacientes con insuficiencia cardiaca y fracción de eyección reducida con o sin diabetes: revisión sistémica
by: Henry Mejia-Zambrano
Published: (2022-04-01)

Inhibidores del SGTL-2 en pacientes con insuficiencia cardiaca y fracción de eyección reducida con o sin diabetes: revisión sistémica
by: Henry Mejia-Zambrano
Published: (2022-04-01)

Impacto de los inhibidores de SGLT2 sobre la función renal en ancianos con diabetes tipo 2 durante el primer año de tratamiento
by: Leonor P.Silva, et al.
Published: (2022-12-01)

Revisão sobre o uso de inibidores de cotransportador sódio-glicose 2 e agonistas de peptídeo 1 em pessoas com diabetes mellitus tipo 2 e doença cardiovascular
by: Juliana Nogueira Garcia, et al.
Published: (2022-04-01)

Inhibidores de SGLT-2 en Nefropatía Lúpica. Podria considerarse una intervención de Nefroprotección
by: Jorge Rico-Fontalvo, et al.
Published: (2022-12-01)

Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo
by: Aleix Cases
Published: (2023-07-01)

Aproximación clínica al consumo de sodio
by: Leonella Luzardo, et al.
Published: (2011-12-01)

Efecto del bicarbonato de sodio y glucosa sobre la fermentación ruminal, equilibrio ácido-base y química sanguínea en borregos
by: Eugenia Candanosa, et al.
Published: (2010-06-01)

Control glucémico en pacientes con diabetes mellitus tipo 2 según esquema de tratamiento
by: Karla Fabela-Mendoza, et al.
Published: (2024-01-01)

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
by: Lucia Scisciola, et al.
Published: (2022-09-01)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
by: Jennifer Matthews, et al.
Published: (2023-09-01)

La Resina-Aloe y su posible uso como inhibidor de corrosión del acero
by: M. Prato de Arias, et al.
Published: (2011-02-01)

The Effect Of SGLT-2 Inhibitors On Improving Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
by: Wasef Sayeh, et al.
Published: (2023-12-01)

Comparative study of sodium-dependent glucose co-transporters in kidneys of Ostrich chickens
by: Piret Hussar, et al.
Published: (2022-07-01)

Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life
by: Ramón Baeza-Trinidad, et al.
Published: (2023-07-01)

A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
by: Jonali Ramani, et al.
Published: (2022-12-01)

Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm
by: Jianyi Li, et al.
Published: (2023-08-01)

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
by: Peng Zhong, et al.
Published: (2023-11-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

Inflammation and prostate cancer: Biological implications and clinical usefulness = Inflamación y cáncer de próstata: implicaciones biológicas y posible utilidad clínica
by: Reyes, Niradiz, et al.
Published: (2014-01-01)

Eliminação urinaria do cloreto de sodio na anemia ancilostomotica
by: W. O. Cruz, et al.
Published: (1944-10-01)

Three Levels of Disease Modification with SGLT-2 Inhibitors: Holy Grail in Vasculopathy
by: Archit Dhaiya; Rajeev Sharma; Nagendra Bhoopathy; Rajeev Agarwal
Published: (2023-07-01)

Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
by: Xiaojun Chen, et al.
Published: (2024-05-01)

Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
by: Věra Čertíková Chábová, et al.
Published: (2022-03-01)

Case Report: Post-gastrectomy reactive hyperinsulinemic hypoglicaemia: glucose trends before and after canagliflozin treatment
by: G. Bellastella, et al.
Published: (2023-08-01)

Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach
by: JÉSSICA B. DE JESUS, et al.
Published: (2022-10-01)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
by: Rendell MS
Published: (2019-03-01)

SGLT1/2 as the potential biomarkers of renal damage under Apoe−/− and chronic stress via the BP neural network model and support vector machine
by: Gai-feng Hu, et al.
Published: (2022-08-01)

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
by: O. Y. Sukhareva, et al.
Published: (2022-02-01)

Relevancia del monitoreo continuo de glucosa en la práctica clínica: revisión de la evidencia
by: Ana María Gómez, et al.
Published: (2018-08-01)

Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Reply of the Anemia group of the Spanish Society of Nephrology
by: Aleix Cases, et al.
Published: (2023-09-01)

Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
by: Aleix Olivella, et al.
Published: (2024-04-01)

The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data
by: Serhat Özçelik, et al.
Published: (2020-03-01)

SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
by: Canan Ersoy
Published: (2020-01-01)

Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats
by: Piotr Londzin, et al.
Published: (2022-11-01)

Sleeve Gastrectomy Surgery Improves Glucose Metabolism by Downregulating the Intestinal Expression of Sodium–Glucose Cotransporter-3
by: Yixing Ren, et al.
Published: (2022-01-01)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
by: Beatriz Fernandez-Fernandez, et al.
Published: (2020-06-01)